Table 1 Patient characteristics.

From: Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146

 

Discovery study

Validation study

CC genotype

CT/TT genotype

p

CC genotype

CT/TT genotype

p

mean ± SD

mean ± SD

mean ± SD

mean ± SD

Age (years)

65.93 ± 9.71

63.60 ± 9.31

0.091

65.34 ± 8.39

66.49 ± 8.43

0.255

Male sex (%)

52.9

46.4

0.427

47.6

54.8

0.268

BMI (kg/m2)

28.60 ± 5.25

28.32 ± 5.30

0.558

29.64 ± 4.79

28.78 ± 3.81

0.164

Waist circumference (cm)

102 ± 13

100 ± 13

0.232

103 ± 11

103 ± 11

0.860

Hypertension (%)

70.0

66.7

0.658

78.1

79.3

0.827

Triglycerides (mg/dl(mmol/l))

129(1.5) ± 57(0.6)

144(1.6) ± 106(1.2)

0.755

170(1.9) ± 125(1.4)

151(1.7) ± 76(0.9)

0.674

LDL-C (mg/dl(mmol/l))

133(3.44) ± 44(1.14)

126(3.26) ± 37(0.96)

0.306

129(3.34) ± 45(1.17)

127(3.29) ± 39(1.01)

0.878

HDL-C (mg/dl(mmol/l))

56(1.45) ± 17(0.44)

59(1.53) ± 20(0.52)

0.291

53(1.37) ± 16(0.41)

55(1.42) ± 19(0.49)

0.645

CAD, significant (%)

48.6

47.6

0.906

45.7

58.5

0.049

Type 2 diabetes (%)

24.3

27.4

0.663

29.5

40.0

0.092

Alcohol consumption (%)

57.9

61.0

0.714

57.4

52.4

0.448

Smoking, current (%)

11.4

25.0

0.032

13.3

16.3

0.524

Glucose, fasting (mg/dl(mmol/l))

105 (5.8) ± 202 (1.1)

116 (6.4) ± 40 (2.2)

0.236

117 (6.5) ± 46 (2.5)

122 (6.7) ± 45 (2.5)

0.087

Glucose, 2 h OGTT (mg/dl)

123 (6.8) ± 47 (2.6)

126 (7.0) ± 63 (3.5)

0.704

151 (8.4) ± 83 (4.6)

153 (8.5) ± 80 (4.4)

0.826

HbA1c (% (mmol/mol))

5.88 (41) ± 0.57 (6)

6.18 (44) ± 0.97 (11)

0.260

6.22 (44) ± 1.21 (13)

6.43 (47) ± 1.25 (14)

0.026

Insulin (µU/ml)

12.73 ± 9.13

12.85 ± 11.19

0.676

13.96 ± 13.84

21.52 ± 77.42

0.299

eGFR (ml/min/1.73 m2)

96.37 ± 16.23

95.94 ± 17.89

0.862

94.12 ± 14.56

93.96 ± 17.48

0.604

ASA treatment (%)

70.0

73.8

0.600

73.3

62.2

0.069

Beta blocker treat. (%)

55.7

44.0

0.149

57.1

54.8

0.719

ACE inhibitor treat. (%)

40.0

27.4

0.098

28.6

31.1

0.670

ARB treat. (%)

10.0

8.3

0.720

11.4

10.4

0.794

Statin treatment (%)

35.7

46.4

0.179

51.4

48.1

0.614

Fibrate treat. (%)

0.0

1.2

0.360

2.9

3.7

0.717

Sulfonylurea treat. (%)

2.9

4.8

0.543

8.6

10.4

0.639

Biguanide treat. (%)

10.0

11.9

0.707

10.5

12.6

0.612

Glitazone treat. (%)

1.4

1.2

0.897

0.0

0.0

n.a.

Insulin treat. (%)

5.7

7.1

0.720

5.7

8.1

0.466

Antidiabetic treat. (%)

17.1

16.7

0.937

17.1

19.3

0.674

  1. The table presents the patient characteristics of the discovery study and of the validation study. Patients were separated with respect to their genotype. Data are given as means ± standard deviations as indicated. Hba1c is given according to DCCT and IFCC -derived units (%; mmol/mol). ACE denotes angiotensin converting enzyme, ARB angiotensin II receptor blocker, ASA acetyl salicylic acid, BMI body mass index, CAD coronary artery disease, which is defined by an angiographically determined coronary artery stenosis with lumen narrowing ≥50%, eGFR the estimated glomerular filtration rate, HbA1c hemoglobin A1c, HDL-C high density lipoprotein cholesterol, and LDL-C low density lipoprotein cholesterol.
Back to article page